Last update 08 May 2025

Enlonstobart

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Recombinant human anti-PD-1 monoclonal antibody(CSPC Zhongqi), 重组抗PD-1全人源单克隆抗体 (石药集团中奇制药)
+ [3]
Target
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
PD-L1 positive Uterine Cervical Cancer
China
25 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PD-L1 positive Uterine Cervical CancerPhase 3-31 Jan 2023
Fallopian Tube CarcinomaPhase 2
China
23 Jul 2021
Peritoneal NeoplasmsPhase 2
China
23 Jul 2021
Platinum-Resistant Epithelial Ovarian CarcinomaPhase 2
China
23 Jul 2021
Ovarian Epithelial CarcinomaPhase 1-01 Sep 2021
Recurrent ovarian cancerPhase 1-01 Sep 2021
Recurrent Platinum-Resistant Ovarian CarcinomaPhase 1-01 Sep 2021
Recurrent Cervical CancerPhase 1
China
31 Jul 2021
Advanced Bile Duct CarcinomaPreclinical
China
01 Sep 2021
Intrahepatic CholangiocarcinomaPreclinical
China
01 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Recurrent Cervical Cancer
Second line | Third line
107
SG001stobart (SG001) 240 mg
(pvnwhdkgez) = nnvghzeitv jhycquvpbd (twgalcnlwq, 20.6 - 38.5)
Positive
24 May 2024
Phase 1
91
(bpwwirmili) = rmjwzqjtap ljrttodesu (kkienxjite, 15.5% - 39.7)
-
21 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free